NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact...
NEW HOPE, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
NEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, Orchestra BioMed or the Company), a biomedical company accelerating high-impact technologies to...
Company hosting in-person R&D day event, focused on atrioventricular interval modulation (AVIM) therapy, including the unmet need in hypertension, mechanism of action, clinical results and...
NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, Orchestra BioMed or the Company), a biomedical company accelerating high-impact technologies to...
Patent estate covering atrioventricular interval modulation (AVIM) therapy includes 37 issued U.S. patents and 73 patents outside the U.S. that collectively comprise over 1,800 claims related to the...
Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with...
Orchestra Announces Appointment of David to Board of Directors
Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be...
NEW HOPE, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (œOrchestra BioMed or the œCompany), a biomedical company accelerating high-impact technologies to...